Physician profile
Frederick Delboy
NPI 1245299932
$7,348.80
in general payments reported to CMS, 2019-2025
40 companies · $593 in 2025
The $593 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,769 · 2020: $1,401 · 2021: $1,383 · 2022: $1,103 · 2023: $645 · 2024: $455 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,608 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,607.66 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $871.83 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Amgen INC. | $676.49 | 2019-2024 | Prolia, Evenity, Otezla |
| Abbvie INC. | $560.24 | 2019-2025 | Ubrelvy |
| Lilly USA, LLC | $522.89 | 2019-2025 | Mounjaro, Jardiance, Kisunla |
| Mylan Specialty L.P. | $442.52 | 2019-2022 | |
| Astellas Pharma US INC | $431.20 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $384.61 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $328.73 | 2019-2025 | |
| Novo Nordisk INC | $325.24 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $322.45 | 2019-2022 | |
| Allergan, INC. | $268.16 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.47 | 2020-2025 | Jardiance, Tradjenta |
| Exact Sciences Corporation | $211.74 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $197.95 | 2021-2023 | Trintellix |
| Daiichi Sankyo INC. | $174.44 | 2021-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Delboy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.